• doctor high-fiving young patient

    Aleta’s novel engager proteins transform cancers so that CAR-T cells can effectively kill every targeted tumor cell

  • Aleta CAR T Engagers (CTEs) are poised to be the optimal and bespoke solution for patients at risk of lymphoma or myeloma relapse

  • older woman supported by medical professional

    Aleta CTEs are simple, specific, potent biologic therapies, off-the-shelf and point-of-care

Aleta Biotherapeutics is pioneering transformation of cancer treatment by enabling CAR T cancer therapies to work more effectively. The Company’s portfolio of multi-antigen CAR T Engagers (CTEs) are simple, biologics designed to enhance the expression of CAR T target antigen in any tumor cell.  

Our CTEs bind to cancer cells to enhance the efficacy of CAR T cell therapies. Aleta CTEs work by increasing cancer target density, preventing resistance and escape from therapy, and increasing the speed and effectiveness with which CAR T cells can kill cancer cells.

Clinical Program: Aleta-001

Our clinical stage program, ALETA 001, has won landmark support and funding from Cancer Research UK for Phase I/II clinical trials and received an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).

ALETA-001 is being developed to treat B cell lymphoma and leukemia patients experiencing relapse following treatment with anti-CD19 CAR T cell therapy, a high unmet need patient population. Phase I/II clinical trials began in February 2024.

(For more information on this trial please visit clinicaltrials.gov (NCT06045910))

In addition, ALETA-001 is planned for PhaseI/II clinical trials in adjunct setting (early dosing after CART therapy.)

ALETA-001: Simple Biologic, GMP, Vialed and Released

Pipeline

Programs

  • ALETA-001 is in Phase I/II Clinical Trials. A CTE that contains the CD19 target protein that is recognized by the approved anti-CD19 CAR T cell therapeutics, which is further linked to an anti-CD20 antibody domain. ALETA-001 is designed to improve the effectiveness of anti-CD19 CAR T therapies by increasing CD19 antigen density and restoring lost CD19 expression. This allows CD19+/CD20+ cancer cells to be easily recognized and killed by anti-CD19 CAR T-cells that were prior administered and are already circulating within a patient. ALETA-001 binds with high affinity to the CD20 cancer antigen to display CD19 protein, which in turn attracts circulating CD19 CAR T cells. ALETA-001 increases CD19 antigen density and prevents cancer escape that commonly occurs due to loss of cancer cell CD19 expression. Therefore, the anti-CD19 CAR T cells have the heightened potential to become more activated and to kill cancer cells more easily (Read Here).

  • ALETA-004 is a preclinical, multi-antigen binding CTE designed to extend the cancer killing activity of CD19 CAR T cells to treat patients with advanced acute myeloid leukemia (AML), a deadly blood cancer. ALETA-004 binds two well- known AML antigens, and links them to CD19 CAR T cells using the same CD19 target protein that is recognized by the approved anti-CD19 CAR T cell therapeutics. The ALETA-004 CTE is the culmination of scientific advances first published by Aleta in 2022 (Rennert et al link).

  • ALETA-005 is a discovery stage CTE that contains the same BCMA target protein that is recognized by the approved CAR T cell therapeutics and is linked to multiple myeloma antigen-binding domains. ALETA-005 is designed to be given alongside BCMA CAR T therapy for the treatment of advanced multiple myeloma patients, and functions by presenting multiple binding sites for the BCMA CAR T cells and optimally stimulating their ability to kill the multiple myeloma cancer cells. Aleta recently presented data from the ALETA-005 program (SITC 2022 link).

  • ALETA-002 and ALETA-003 are designed to treat solid tumor cancers. They use CD19-protein based CTEs directed to well-validated the solid cancer cell antigens. Each is designed to be incorporated into a CD19 based CAR T therapy, to connect non-B cell cancers to CD19 CAR T cells to enable cancer cell killing. This strategy evokes fundamental immunology – the interaction of T cells with CD19-expressing B cells – to drive increased CAR T cell expansion and persistence (Ambrose et al).

Our Team

Satish is a General Partner at Advent Life Sciences and serves as a CEO of Aleta Biotherapeutics since January 2024. Previously, He was a CEO of BioMotiv (now under Advent Life Sciences). He was a co-founder and CEO of NeoGenesis (acquired by Schering-Plough, now Merck), Co-founder and President of Verastem (NASDAQ: VSTM) and co-founder of Elicio Therapeutics (NASDAQ: ELTX). He also served as Vice President and Site Head at Schering-Plough Research Institute in Cambridge, Massachusetts and Vice President and Site Head at Bristol-Myers Squibb. He obtained a PhD in Biochemistry from Punjab University in India and did his postdoctoral research at Whitehead Institute at Massachusetts Institute of Technology, Cambridge, MA.

Paul is a noted research scientist and biotechnology executive with extensive strategic and leadership experience. His industry expertise spans bench to IND to clinical trials for biologics, small molecules and cellular therapeutics. His recent accomplishments include the launch of successful new biotech companies. In 2012 he engaged with MPM Capital to launch CoStim Pharmaceuticals, one of the first private immuno-oncology companies (bought by Novartis), In 2013 he partnered with X-Chem Inc to create X-Rx Discovery, a privately held drug discovery company focused on oncology, inflammation, and fibrosis that successfully out-licensed programs in oncology and fibrosis.

Paul’s ability to work so broadly across the industry grew from his outstanding early career at Repligen and Biogen, highlighted by multiple successful drug-development campaigns, over 40 patents filed and granted, and approximately 100 peer-reviewed publications including publications in Nature Reviews Drug Discovery, Annual Reviews, Immunity, Journal of Experimental Medicine, Journal of Clinical Investigation, and PNAS USA. In 2015 he co-authored and edited the book “Novel Therapeutic Approaches to the Treatment of Cancer”, for Springer Nature. Paul continues to lecture and write extensively. His seminal observations on drug development, immunology, immuno-oncology and cell therapy are can be found at sugarconebiotech.com Blog, on slideshare.net/PaulDRennert and via his highly influential Twitter commentary @PDRennert.

Roy joined Advent in 2015 and brings over 25 years of drug discovery, drug development and entrepreneurial experience

Roy obtained a D.Phil. from Oxford University for work on zinc metalloenzymes before becoming Assistant Professor of Pathology at Harvard Medical School. Roy then spent 15 years at Biogen Inc, where he discovered the pathway that enabled the development of the drug TysabriTM, used to treat severe multiple sclerosis. At Biogen, Roy was Senior Director, Exploratory Research and was responsible for overseeing all immunology and inflammation-directed research.

Since leaving Biogen, Roy has cofounded multiple Biotechnology Companies, including: Albor Biologics, set up to commercialize IP around the function of the leukocyte activation molecule CD69 from the University of Madrid; Avila Therapeutics, set up to develop covalent small molecule drugs using structure-based drug design; and Alvos Therapeutics, set up to develop novel cell surface tumor proteins identified at M D Anderson Cancer Center by Drs. Pasqualini and Arap through in vivo phage display.

Roy is a Founder and Director of the portfolio Company Aleta Biotherapeutics, and an advisor to other Advent portfolio Companies.

Lynne Kelley, MD, FACS provides medical and clinical expertise as a consultant for Aleta. She brings more than a decade of experience directing clinical development and global expansion of novel device and pharmaceutical products at both emerging and established life sciences companies. Lynne is a Board Certified General and Vascular Surgeon. Lynne has held executive level positions as chief medical officer (CMO) in oncology and rare disease focused companies Servier and X4 Pharmaceuticals. The biologic orthopedic company Histogenics where she led the development of restorative cell therapies to replace damaged cartilage and oversaw the completion of a Phase 3 clinical trial and regulatory submission for the company’s lead program and Senseonics a novel implantable continuous glucose monitor company. Lynne previously held medical leadership positions at global companies such as Becton, Dickinson, Kimberly-Clark, and Boston Scientific. Lynne received her medical degree from Dartmouth Medical School ,trained at Dartmouth Hitchcock Hospital and Massachusetts General Hospital and was a practicing vascular surgeon and interventionalist at Yale University. Lynne was named Fellow of the American College of Surgeons, was awarded an NIH research grant at Harvard and the Marco Polo Fellowship studying minimally invasive surgery for carotid and peripheral vascular diseases at Hospital Henri Mondor, Paris France. Lynne holds several patents for both device invention and method of use for drugs and has authored numerous articles for peer-reviewed publications. She previously served on the board of Equalize Health, a non-profit medical device company with a mission to improve care in developing countries and is presently on the board of Dartmouth’s Global Center for Health Equity.

Lisa has over a decade of experience in the pharmaceutical industry, with most experience in biologics, and cell and gene therapies. She has served as Global Regulatory Lead for multiple companies based in the US and UK including early phase startup companies that have yet to establish a regulatory department, growing companies that are moving from early phase to a more established development team, late stage development companies preparing for marketing authorizations, and commercial organizations. She has led the preparation and submission of Orphan Drug Designations (ODD), Regenerative Medicine Advanced Therapy (RMAT), Pre-INDs, INDs, Scientific Advice, Pre-MAA, MAAs and other Health Authority interactions.

Therapeutic areas include renal disease, autoimmune disorders, rheumatology, oncology, rare disease in both adults and pediatrics, and neurological disease (rare pediatric neurological disease, Alzheimer’s disease, ALS and Parkinson’s disease).

Before joining the pharmaceutical industry, Lisa held varying academic positions at both the University of Colorado, Boulder and the University of the Witwatersrand. Prior to her academic career she worked in clinical practice as a Physiotherapist in South Africa. Lisa received her Bachelors and Masters in Physiotherapy and Ph.D in Physiology from the University of the Witwatersrand, South Africa.

Christine Ambrose, principal investigator

Christine has worked as a Molecular Biologist focused on Immunology and Neurology projects, leading a group at Biogen for over 20 years. Her main contribution at Biogen was identifying receptor-ligand interactions of TNF family ligands. Her group identified BAFF-R as a novel receptor for the B cell protein, BAFF and showed that BCMA was also a receptor for BAFF. Christine joined Aleta Biotherapeutics in 2016 and as a Principal Investigator, leads the group in the laboratory. The team brought the ALETA-001 molecule from concept to clinical development in 3 years while advancing the rest of the Aleta pipeline. She has been involved in all aspects of the ALETA-001 preclinical studies and is now focused on bringing forward ALETA-004 and ALETA-005.

Christine earned her B.S in Biochemistry at the University of Minnesota and her Ph.D. in Chemistry from Purdue University. Her postdoctoral research was in the Neurogenetics Unit at Massachusetts General Hospital where she identified and characterized the gene for Huntington’s disease.

Christine has published 60 scientific papers and earned 13 patents.

Lihe has been working in biological industries for 30+ years. Her work has been focused on protein chemistry with experience at Biogen and AB Biosciences. Lihe Joined Aleta Biotherapeutics in 2016 where her research interest shifted to CAR-T biology and involved in in vitro analysis of studying CAR-T related biological activities.

Lihe earned her bachelor’s in biology at Beijing Normal University, her MS in Biology from UMass Boston and her Ph.D. in Molecular Biology from Northeastern University. Her postdoctoral experience was at Joslin Diabetes Center involved studying Protein Kinase C pathway.

Lihe has published 77 scientific papers and earned 3 patents.

Lan has been working in the Immunology and Oncology research fields for 20+ years. She developed and optimized in vitro and in vivo research methods to fulfill the challenging needs of specific projects at AVEO Oncology and Biogen. One key area of work at Biogen was to optimize confocal microscopy methods for subcellular localization of target proteins and molecular interactions to better understand cell signaling pathways. Since joining Aleta Biotherapeutics in 2016, she used her broad skill set to develop cell binding and restimulation assays, run cytotoxicity assays and optimize CAR-T production.

Lan obtained her BS and MS in biology from Fudan University and her PhD degree from Purdue University where she developed an expertise in insect biochemistry and molecular biology.

Lan’s reliable research data made significant contributions to project advancements, 27 peer-reviewed publications and IND filings.

Katie joined Aleta in 2022 with 8+ years of program and project management. Prior to joining the team, she was a consultant at Beacon Capital Partners, working with the infrastructure team to develop their IT programs and applications. Prior to that she worked at Novartis as a project analyst in the IT division supporting biomedical application programs for multiple campuses.

Katie earned her BS in Business Management from Newbury College and her MA in Corporate Communications and Public Relations from Sacred Heart University.

Board of directors

Paul Rennert, PhD
Director

Paul is a noted research scientist and biotechnology executive with extensive strategic and leadership experience. His industry expertise spans bench to IND to clinical trials for biologics, small molecules and cellular therapeutics. His recent accomplishments include the launch of successful new biotech companies. In 2012 he engaged with MPM Capital to launch CoStim Pharmaceuticals, one of the first private immuno-oncology companies (bought by Novartis), In 2013 he partnered with X-Chem Inc to create X-Rx Discovery, a privately held drug discovery company focused on oncology, inflammation, and fibrosis that successfully out-licensed programs in oncology and fibrosis.

Paul’s ability to work so broadly across the industry grew from his outstanding early career at Repligen and Biogen, highlighted by multiple successful drug-development campaigns, over 40 patents filed and granted, and approximately 100 peer-reviewed publications including publications in Nature Reviews Drug Discovery, Annual Reviews, Immunity, Journal of Experimental Medicine, Journal of Clinical Investigation, and PNAS USA. In 2015 he co-authored and edited the book “Novel Therapeutic Approaches to the Treatment of Cancer”, for Springer Nature. Paul continues to lecture and write extensively. His seminal observations on drug development, immunology, immuno-oncology and cell therapy are can be found at sugarconebiotech.com Blog, on slideshare.net/PaulDRennert and via his highly influential Twitter commentary @PDRennert.

    Raj joined Advent in 2005 bringing over 20 years of experience in biomedical research and as an entrepreneur and investor.

    After gaining an MA and DPhil from Oxford University, he pursued a successful academic career in molecular medicine before co-founding Oxford GlycoSciences (IPO on LSE and NASDAQ). Following its sale to UCB-Celltech, he became Chairman of Galapagos nv, a member of the Supervisory Board of the Novartis Venture Fund and a founding Director of Celldex Therapeutics.

    Since joining Advent, Raj has been mainly involved in founding and supporting our portfolio Companies that are involved in the discovery of new medicines. Raj currently serves on the Board of several portfolio Companies including Arrakis, Aura BioSciences, Levicept and Rappta Therapeutics.

    Raj currently serves on the Board of several portfolio Companies including Arrakis, Aura Biosciences and Levicept.

Damià Tormo has spent the last 20 years working in healthcare and the biotech industry. He is currently Managing Partner and co-founder of Columbus Venture Partners, with four Funds in Biotech under management. He is founder of several biotech companies such as Highlight Therapeutics, Artax Biopharma, Viralgen, Vivet Therapeutics, Polypeptide Therapeutic Solutions, Tyris Therapeutics or Radioterapia de Protones. He has also served as CEO of Highlight Therapeutics and Artax Biopharma Inc. for several years. Damia is currently Director of Artax, Highlight, Integra, Minoryx, Tyris, Cocoon, Aleta and Syngoi. Moreover, Damia is the President of Fundación Columbus, a non-profit organization that develops advanced therapies for children with cancer and ultra-rare genetic diseases.

Before this, he was a researcher in different institutions such as the Uniklinik Bonn, University of Michigan or the Spanish National Cancer Center (CNIO). He received several awards related to innovation and entrepreneurship, including the 2017 Princess of Girona Foundation Award, TR35 from MIT or the Biogen Foundation Award. Damia holds a MSc in Biological Sciences from the University of Valencia, MBA from IE Business School and PhD in Immunology and Molecular Genetics from the Rheinische Friedrich-Wilhelms-Universität Bonn, Germany.

Eva-Lotta Allan has more than 30 years of experience in the healthcare industry. During this time, she has been a senior executive and Board member at both public and private companies. Most recently, Eva-Lotta was Chief Business Officer (and previously a Board Member) at Immunocore, where she held full responsibility for all aspects of business development and played an instrumental role in the $320 million fundraising in 2015. Prior to this, Eva-Lotta served as Chief Business Officer and member of the Executive Committee and Euronext IPO team for Ablynx NV, acquired in 2018 by Sanofi for EUR 3.9 billion.

Eva-Lotta also held senior positions at Vertex Pharmaceuticals (Europe) Ltd where she was on the Vertex Europe Ltd board, Oxford Asymmetry International plc (now Evotec), Oxford Glycosciences (now UCB) and Amersham International (now GE Healthcare). Eva-Lotta Allan currently serves as Chair of Maxion Therapeutics and Draupnir Bio. She is also Non-Executive Director of Almirall (and Chair of their Nomination and Remuneration Committee) and Crescendo Biologics.. Eva-Lotta previously served as a Board Member of the UK BioIndustry Association (BIA) and of Isconova.

Dr. Keswani is an accomplished physician-scientist with executive leadership experience in both large pharma and small biotech. He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom. Sanjay was Senior Vice President of R&D at Hoffman La Roche, and Vice President of Exploratory and Clinical Translational Research at Bristol-Myers Squibb, where he was responsible for multiple therapeutic areas including Immunology, Neuroscience, Rare Diseases, Fibrosis and Virology. He has held CEO and CMO positions in biotech with experience of successful Nasdaq IPO (Annexon), acquisition (MiroBio by Gilead), venture fundraising (Series A, B, D rounds), and multiple industry partnerships. Sanjay has been instrumental in the development of several approved medicines, including Risdiplam, Emgality, Faricimab, Cymbalta, Aimovig and Deucravacitinib.

Sanjay completed his residency in Neurology and fellowships in Neuroimmunology and Neurophysiology at Johns Hopkins. He graduated in medicine at St. Bartholomew’s Hospital (UK’s oldest hospital founded in 1123) and holds a First Class honors BSc degree from St. Mary’s Hospital, London in Pathology & Basic Medical Sciences (Immunology).

Scientific Advisory Board 

Christine Brown, PhD is the Heritage Provider Network Professor in Immunotherapy at City of Hope Comprehensive Cancer Center. Her research has focused on advancing chimeric antigen receptor (CAR) T cell therapy for the treatment of cancer. As Deputy Director of the T Cell Therapeutics Research Laboratory (TCTRL), Christine provides scientific oversight for the translational research programs and ongoing phase I clinical trials evaluating CAR T cell therapy at City of Hope. Christines’s research laboratory is focused on advancing CAR T cell therapy for the treatment of brain tumors. Her efforts to develop glioblastoma-targeted CAR T cells, improve T cell manufacturing, and optimize routes of T cell delivery have led to the initiation of several first-in-human clinical trials, including ongoing clinical testing of IL13Rα2- and HER2-targeted CAR T cell therapy for the treatment of recurrent glioblastoma. Christine’s ongoing research efforts also aim to develop strategies to limit tumor antigen escape and to overcome the suppressive tumor microenvironment, critical challenges limiting the effectiveness of CAR T cell therapy for treatment of solid tumors.

Christine received her doctoral degree from the University of California, Berkeley, and was a Leukemia & Lymphoma Scholar during her post-doctoral fellowship at Pennsylvania State University. Her scientific contributions in the development and optimization of tumor-specific CAR T cells for the treatment of brain tumors are supported by the California Institute for Regenerative Medicine (CIRM), National Institutes of Health, Ivy Foundation, Gateway for Cancer Research, Rising Tide and Norris Foundation.

Christopher Klebanoff, MD is cellular immunologist and medical oncologist with over 20 years of experience in the pre-clinical and early stage clinical development of T cell-based immunotherapies for the treatment of cancer. Prior to joining Memorial Sloan Kettering and the Parker Institute for Cancer Immunotherapy in 2016, he was a Howard Hughes Medical Institute Research Scholar and Assistant Clinical Investigator at the National Cancer Institute in Bethesda, Maryland.

Christopher pioneered the paradigm that T cell subsets with the memory-like attributes of self-renewal and multipotency are a critical determinant for adoptive immunotherapy efficacy. Further, he resolved how host lymphodepletion – a standard practice for nearly all cellular immunotherapies – enhances the potency of adoptively transferred T cells through the removal of homeostatic cytokine “sinks.” The Klebanoff laboratory is currently focused on the discovery and immunologic targeting of shared neoantigens resulting from recurrently mutated driver genes using TCR gene therapy.

Clinically, Christopher has contributed to the successful early phase development of numerous T cell-based therapies, many of which have been successfully licensed to commercial partners. These include an anti-CD19 chimeric antigen receptor (CAR) that would become FDA approved (Yescarta®), tumor infiltrating lymphocyte therapy for the treatment of melanoma (Lifileucel) and other common cancers, and TCR gene therapies targeting epitopes derived from NY-ESO-1 (Letetresgene), MAGE-A3, and HPV16.

Christopher is an elected member of the American Society for Clinical Investigation (ASCI) and recipient of several prestigious awards, including the Damon Runyon Clinical Investigator Award and a National Institutes of Health MERIT Award.

James Mulé, PhD is the Associate Center Director for Translational Science and the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment. James’ role as Associate Center Director, Translational Science is, in part, to oversee Moffitt’s four, transdisciplinary Centers of Excellence, the Cell Therapies Facility, as well as the Office of Innovation and Industry Alliances. He acts as a facilitator to translate laboratory-based research into viable treatments for cancer patient benefit. He is adept at fostering a collaborative environment that weaves laboratory scientists and clinicians together into a singular effort to develop new or improved prevention and treatment interventions across the cancer care continuum, which is evident even in his own research efforts.

James received a special individual Ph.D. (IPh.D.) degree in Tumor Immunology and Immunotherapy from the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington. Dr. Mulé, who was designated a “Master of Immunology” by the American Association for Cancer Research, serves on Advisory Boards of numerous biotechnology and pharma companies (e.g., OncoPep, AffyImmune, Vycellix, Ankyra, Vault Nano, Turnstone, Aleta, among others). Prior to his arrival in Tampa, James helped to launch and scientifically direct two biotechnology companies in Palo Alto, CA, which were acquired by Sandoz (now Novartis). He also had prepared both Novartis and Spark Therapeutics for presentations to the FDA, leading to the approval of Kymriah and Luxturna, respectively. James remains a long-standing special government employee to the FDA (both CDER and CBER) and the NCI. He was Chair of the Cellular, Tissue, and Gene Therapy Advisory Committee of CBER, FDA. James has published over 250 articles in the areas of cancer vaccines and cancer immunotherapy.

Marco Schupp is a Clinical Development physician with a distinguished career spanning over 20 years. During this time he led groundbreaking initiatives in oncology and hematology.

As the Global Development Lead for axicabtagene-ciloleucel (axi-cel) at Kite Pharma, Marco spearheaded the development of innovative CAR T-cell therapies. He served as a Medical Monitor for the first randomized phase 3 CAR T-cell study in DLBCL and for phase 2 programs with axi-cel in indolent lymphoma.

Prior to his tenure at Kite Pharma, Marco held clinical development positions at Amgen, where he contributed significantly to clinical and early development efforts. Notably, he served as a clinical scientist for multiple myeloma programs and led early development initiatives for a small molecule FIH program.

Before transitioning to the biotech sector, Marco made significant contributions as a Medical Manager at Sanofi-Synthelabo (Germany), focusing on clinical trials with oxaliplatin.

Marco's academic journey commenced with a distinguished MD from the University of Freiburg, Germany. He further enriched his medical acumen through 12 years of clinical practice in internal medicine, hematology, and medical oncology at the University Hospitals in Freiburg and Tübingen (Germany), James Paget University Hospitals in Great Yarmouth, UK, and University College London Hospitals.

Sarah K Tasian, MD is a pediatric oncologist and physician-scientist at the Children’s Hospital of Philadelphia (CHOP) and an Associate Professor of Pediatrics at the University of Pennsylvania School of Medicine who is interested in development of molecularly-targeted therapeutics for children with high-risk leukemias. She specialises in the clinical care of children with leukemia and lymphoma, serves as the Chief of the Hematologic Malignancies Program at CHOP, holds the Joshua Kahan Endowed Chair in Pediatric Leukemia at CHOP, and is an internationally-recognized expert in pediatric ALL and AML. Her bench-to-bedside and bedside-back-to-bench translational laboratory research program focuses upon testing of small molecule inhibitors and chimeric antigen receptor (CAR) T cell immunotherapies in genetic subsets of childhood ALL and AML. Dr Tasian has leadership roles in the Children’s Oncology Group (COG) ALL and Myeloid Diseases committees and the Leukemia & Lymphoma Society PedAL/EuPAL consortium, is the COG Developmental Therapeutics committee Vice-Chair of Biology for Hematologic Malignancies, and leads or co-leads several national or international early phase clinical trials testing precision medicine therapies in children with high-risk leukemias.

News & Publications

News

Publications

Blogs

Blog
Recent CAR-T Clinical Studies in Glioma and Glioblastoma Patients
The PD-1/PD-L1 Pathway and CAR-T Cells: Stop Making Sense
A Deep Dive Into The Use of Cytokines With CAR T Cells